炎症性肠病(IBD)在胃肠病学领域提出了持续的挑战,需要不断探索创新的治疗策略。与现有治疗方式相关的有限疗效和潜在副作用强调了对IBD治疗新方法的迫切需要。对该疾病复杂发病机制的理解的最新进展揭示了有希望的治疗靶点,关注肠道微生物组,免疫失调,和遗传倾向。本摘要深入探讨了对IBD治疗新途径的迫切需求,检查潜在的治疗目标,例如,磷酸二酯酶4(PDE4)抑制剂,免疫系统,酪氨酸激酶受体(TYK),Toll样受体(TLRs),肠道微生物群的调节,干细胞疗法,纤维化管理,白细胞介素(IL)调节和氧化应激,并提供了对近期突破的见解,这些突破预示着IBD治疗领域的变革时代。精准医学的进展,生物制剂,小分子抑制剂,微生物组调节技术的探索是关键的里程碑,为提高疗效提供了新的希望,减少副作用,并改善IBD治疗的患者预后。
UNASSIGNED: Inflammatory Bowel Disease (IBD) poses a persistent challenge in the realm of gastroenterology, necessitating continual exploration of innovative treatment strategies. The limited efficacy and potential side effects associated with existing therapeutic modalities underscore the urgent need for novel approaches in IBD management. This study aims to examine potential therapeutic targets and recent advancements in understanding the disease\'s intricate pathogenesis, with a spotlight on the gut microbiome, immune dysregulation, and genetic predispositions.
UNASSIGNED: A comprehensive review was conducted to delve into the pressing demand for new avenues in IBD treatment. The study examined potential therapeutic targets such as phosphodiesterase 4 (PDE4) inhibitors, immune system modulators, Tyrosine kinase receptors (TYK), Toll-like receptors (TLRs), modulation of the gut microbiota, stem cell therapy, fibrosis management, interleukins (ILs) regulation, and oxidative stress mitigation. Additionally, advances in precision medicine, biologics, small molecule inhibitors, and microbiome modulation techniques were explored.
UNASSIGNED: The investigation unveiled promising therapeutic targets and provided insights into recent breakthroughs that herald a transformative era in the therapeutic landscape for IBD. Advances in precision medicine, biologics, small molecule inhibitors, and the exploration of microbiome modulation techniques stood out as pivotal milestones in the field of gastroenterology.
UNASSIGNED: The findings offer renewed hope for enhanced efficacy, reduced side effects, and improved patient outcomes in the treatment of IBD. These innovative approaches necessitate continual exploration and underscore the urgent need for novel strategies in IBD management, potentially revolutionizing the realm of gastroenterology.